Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study by Xian-dong Yu, Huihuang Huang, Yanmei Jiao, Jing Li, Xing Fan, Dawei Zhang, Fu-sheng Wang

“…Results In 666.7 person-years, hypertriglyceridemia occurred in 140 patients (triglyceride ≥2.3 mmol/L [200 mg/dL]), and the incidence rate was 21.0 per 100 person-years (Patients who took the lamivudine [3TC] + tenofovir disoproxil fumarate [TDF] + efavirenz [EFV] regimen accounted for 77.0% of the total patients.). …”
Get full text

Recurrent pneumothorax in a human immunodeficiency virus-positive patient with multidrug-resistant tuberculosis: a rare case of bronchopleural fistula: a case report by Lydia Nakiyingi, Joseph Baruch Baluku, Willy Ssengooba, Sharon Miriam Namiiro, Paul Buyego, Ivan Kimuli, Susan Adakun

“…The patient was given multidrug-resistant tuberculosis treatment that included bedaquiline, isoniazid, prothionamide, clofazimine, ethambutol, levofloxacin, and pyrazinamide and switched to second-line anti-retroviral therapy that included tenofovir/lamivudine/lopinavir/ritonavir. Chest X-ray revealed a hydro-pneumothorax, following which a chest tube was inserted. …”
Get full text

<i>Moringa oleifera</i> Lam Leaf Extract Stimulates NRF2 and Attenuates ARV-Induced Toxicity in Human Liver Cells (HepG2) by Siqiniseko S. Ndlovu, Anil A. Chuturgoon, Terisha Ghazi

“…Liver (HepG2) cells were treated with individual ARV drugs: Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), and Lamivudine (3TC) for 96 h, followed by MO leaf extracts for 24 h. …”
Get full text

Renal dysfunction among adult HIV/AIDS patients on antiretroviral therapy at a tertiary facility in Ghana by Dorcas Obiri-Yeboah, Yaw Asante Awuku, Wonderful Alofa, Alice Charwudzi, Ebenezer Aniakwa-Bonsu, Evans Obboh, Paul Nsiah

“…Results The mean age (years) of participants was 45.5 years (±11.6) with 288 (65.4%) being on Tenofovir based ART regimen. The mean eGFR was found to decrease from 112.4 ml/min/1.73 m at baseline, to 103.4 ml/min/1.73 m after 6 months on ART and to a mean of 99.4 ml/min/1.73 m at recruitment into this study. …”
Get full text

BK polyomavirus associated progressive multifocal leukoencephalopathy in a person living with HIV by Brendan O'Kelly, Amy Keane, Emma Devitt, Andrew Lockhart, Deirdre O'Rourke, Fiona Lyons

“…The patient was commenced on tenofovir alafenamide fumarate/emtricitabine/darunavir/cobicistat in combination with dolutegravir 50mg twice daily. …”
Get full text

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study... by Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto

“…Calendar years, HIV-risk factor, higher baseline cholesterol and an InSTI-based previous regimen predicted TD, whereas lamivudine+dolutegravir therapy and previous tenofovir use were protective. VF was the cause of TD in 6/123 cases with darunavir/r, 4/97 with atazanavir/r and 3/21 with dolutegravir. …”
Get full text

Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B by Jihye Lim, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Han Chu Lee, Yeonjung Ha

“…Methods: We conducted a multicenter retrospective cohort study to validate the CAGE-B and SAGE-B scores, HCC prediction models developed for Caucasian patients receiving entecavir (ETV) or tenofovir (TFV) for >5 years. Consecutive patients who started ETV or TFV at two hospitals in Korea from January 2009 to December 2015 were identified. …”
Get full text

Evaluation of Platelet Activation by HIV Protease Inhibitors &ndash; The HIV-PLA II Study by Kann G, Owasil J, Kuczka K, Haberl A, Wolf T, Khaykin P, Harder S, Stephan C, von Hentig N

“…Results of the previous HIV-PLA I-study lead to the assumption that platelet activation could play a substantial role in increasing CVE risks.Methods: The open label, monocentric HIV-PLA II-study investigated HIV-1-infected, therapy-naïve adults (n=45) starting with cART, consisting either of boosted PI (atazanavir, n= 6, darunavir, n=11), NNRTI (efavirenz, n=14) or integrase inhibitor (raltegravir, n=14), each plus tenofovir/emtricitabine co-medication. Main exclusion criteria were tobacco smoking, the intake of NSAIDs or abacavir or past CVE. …”
Get full text

LEISHMANIOSE TEGUMENTAR DISSEMINADA E VISCERALIZAÇÃO EM INDIVÍDUO IMUNOSSUPRIMIDO GRAVE: A IMPORTÂNCIA DO CONTEXTO AMBIENTAL PARA O DIAGNÓSTICO DIFERENCIAL by Raisa Lamara Cruz Dos Santos, Rita Catarina Medeiros de Sousa, Julius Caesar Mendes Soares Monteiro, Lorena de Nazaré dos Reis e Silva Gomes, Brenda Lira Carvalho

“…Paciente apresentava história de tratar HIV desde 2021 com tenofovir + lamivudina + dolutegravir e apresentava, na consulta, carga viral não detectável, porém contagem de células TCD4 de 61 cels/mm³, além de hemograma demonstrando bicitopenia (anemia + leucopenia). …”
Get full text

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B by Mi Sung Park, Beom Kyung Kim, Kyung Sik Kim, Ja Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Oidov Baartarkhuu, Kwang Hyub Han, Chae Yoon Chon, Sang Hoon Ahn

“…The safety profiles were similar in each arm.ConclusionsThere was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.…”
Get full text

Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients by Maryam Gohar, Irshad Ur Rehman, Amin Ullah, Muhammad Ajmal Khan, Humaira Yasmin, Jamshaid Ahmad, Sadia Butt, Ajaz Ahmad

“…N236T, a mutation that gives rise to tenofovir and adefovir resistance, was observed in two (5%) patients. …”
Get full text

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, A... by Muche Belete A, Seifu D, Menon M, Amogne W, Shewa A, Adela Tefera A

“…Thus, this study compares the mean values of lipid profile differences of HIV patients on ATV/r-based regimen compared to efavirenz (EFV)-based regimen, while the background is Tenofovir Disoproxil Fumarate/lamivudine.Materials and Methods: A comparative hospital-based cross-sectional study was conducted among adult HIV-infected patients at Zewditu Memorial Hospital, Addis Ababa, Ethiopia, from July&ndash;September 2017. …”
Get full text

Efficacy and Safety of Pre-Exposure Prophylaxis to Control HIV and Sexually Transmitted Infection Among Men Who Have Sex With Men: Protocol for a Single-Arm Interventional Study by Junko Terada-Hirashima, Daisuke Mizushima, Misao Takano, Daisuke Tokita, Shinichi Oka

“… BackgroundPre-exposure prophylaxis (PrEP) against HIV infection is a new approach that involves the prophylactic use of the anti-HIV drug Truvada (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) by people not infected with HIV. …”
Get full text

Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study. by Geetha Beauchamp, Sybil Hosek, Deborah J Donnell, Kwun C G Chan, Brian P Flaherty, Peter L Anderson, Bonnie J Dye, Nyaradzo Mgodi, Linda-Gail Bekker, Sinead Delany-Moretlwe, Connie Celum, HPTN 082 study team

“…We assessed the predictive value of HPRM scores with PrEP adherence, defined as tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots, as a continuous measure and dichotomized as high PrEP adherence (≥700 fmol/punch).…”
Get full text

Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory analysis by Lufuno G. Mavhandu-Ramarumo, Lisa A.M. Tambe, Nontokozo D. Matume, David Katerere, Pascal O. Bessong

“…Method: Concentrations of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) in the plasma and hair of individuals initiating ART were analysed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. …”
Get full text

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line an... by Jenny Svärd, Sabina Mugusi, Doreen Mloka, Ujjwal Neogi, Genny Meini, Ferdinand Mugusi, Francesca Incardona, Maurizio Zazzi, Anders Sönnerborg

“…According to national guidelines, the default first-line regimen is tenofovir + lamivudine + efavirenz, but variations including nevirapine, stavudine or emtricitabine can be considered. …”
Get full text

Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers by Conar R. O’Neil, Stephen E. Congly, M. Sarah Rose, Samuel S. Lee, Meredith A. Borman, Carmen L. Charlton, Carla Osiowy, Mark G. Swain, Kelly W. Burak, Carla S. Coffin

“…In the NA-treated group (28% entecavir, 68% tenofovir, 4% lamivudine), no significant change in qHBsAg levels occured with time. …”
Get full text

Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy by Carmine Rossi, Janet Raboud, Sharon Walmsley, Curtis Cooper, Tony Antoniou, Ann N. Burchell, Mark Hull, Jason Chia, Robert S. Hogg, Erica E.M. Moodie, Marina B. Klein, the Canadian Observational Cohort (CANOC) Collaboration

“…Additional factors associated with incident CKD were female sex, increasing age after 40 years, lower baseline eGFR below 100 mL/min/1.73m2, increasing HIV viral load and cumulative exposure to tenofovir and lopinavir. Conclusions HCV co-infection was associated with an increased risk of incident CKD among HIV-infected patients initiating cART. …”
Get full text

Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review by Velásquez PA, Hernandez JC, Galeano E, Hincapié-García J, Rugeles MT, Zapata-Builes W

“…Using these tools, new uses for approved drugs such as chloroquine, hydroxychloroquine, ivermectin, zidovudine, ribavirin, lamivudine, remdesivir, lopinavir and tenofovir/emtricitabine have been conducted, showing effectiveness in vitro and in silico against SARS-CoV-2 and some of these, also in clinical trials. …”
Get full text

Long‐Term Change in Bone Mineral Density in Women Living With HIV: A 10‐Year Prospective Controlled Cohort Study by Heather M. Macdonald, Evelyn J. Maan, Claudie Berger, Hélène C. F. Côte, Melanie C. M. Murray, Neora Pick, Jerilynn C. Prior, for the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children: CARMA

“…Lifetime cART duration and tenofovir use were not associated with aBMD 10‐year percent change. …”
Get full text